MIBC: Bladder sparing warrants careful consideration
“I think it’s time to realize that there are other options besides cystectomy, and that the other options should at least be discussed and entertained,” says Alexandre Zlotta, MD, PhD, in this video.
Bladder-sparing treatments, including trimodal therapy, should be carefully considered as alternatives to cystectomy in patients with muscle-invasive bladder cancer (MIBC).
That was the key take-home message of Alexandre Zlotta, MD, PhD, of Mount Sinai Hospital and the University of Toronto, who spoke at the Society of Urologic Oncology annual meeting in Phoenix.
In this video, Dr. Zlotta talks to Urology Times about involving MIBC patients in the treatment decision, how to monitor patients undergoing bladder preservation, and the importance of a specialized, multidisciplinary center in a bladder preservation program.
“I think it’s time to realize that there are other options besides cystectomy, and that the other options should at least be discussed and entertained,” Dr. Zlotta said.
Dr. Zlotta is a consultant for Ferring, Sanofi-Aventis, 3D Biopsy, and Sanofi-Pasteur.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
